FDA Is Unsure About Compounding, but This Nominee Has a View – ConscienHealth
FDA is in a quandary about compounding of the new obesity drugs, semaglutide and tirzepatide. The nominee to lead FDA has an interest.
Related Articles
Explosive Growth in Extremely Severe Obesity (Under the Radar) – ConscienHealth
Explosive growth in the most severe obesity should put to rest any happy talk about obesity prevalence declining.
Quick Takes: Luiz Ybarra and Zachary Singer on the DRIVE-STEMI Study
Luiz F. Ybarra, MD, PhD, and Zachary Singer, MD, explain why the data support less restrictive driving guidance following a STEMI.
Progression of Atrial Cardiomyopathy Predicts Subsequent Stroke: An Analysis of Left Atrial Low-Voltage Areas in Patients With Atrial Fibrillation Ablation | Circulation: Arrhythmia and Electrophysiology
View all available purchase options and get full access to this article. Ono K, Iwasaki YK, Akao M, Ikeda T, Ishii K, Inden Y, Kusano…
American Heart Association Journals
The Journal of the American Heart Association (JAHA) eagerly invites authors to submit manuscripts for our upcoming Spotlight Collection, scheduled for publication in August 2025.…
Join our Cloud HD Video Meeting
Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile,…
Colorectal Cancer Linked with Increased Risk of Cardiovascular Mortality – American College of Cardiology
Contact: Nicole Napoli, nnapoli@acc.org, People diagnosed with colorectal cancer are significantly more likely to die of cardiovascular causes than the general population, especially in the…
Acute Effects of Enhanced External Counterpulsation in Adults With Fontan Circulation:
AbstractBackgroundPatients with Fontan circulation exhibit reduced cardiac output.ObjectivesThe purpose of this study was to study the safety and acute hemodynamic effects of enhanced external coun…
Acute Myocardial Infarction and Stage E Shock: Insights From the RECOVER III Study
The present analysis reports characteristics and outcomes of Society of Cardiovascular Angiography & Interventions (SCAI) stage E shock patients with acute myocardial infarction with cardiogenic…
Newborns with congenital heart defects face elevated cancer risk
Mothers of these children also appear to be at an increased risk of cancer, though researchers do not quite understand why.
Stage E Cardiogenic Shock: Hold ‘Em, Fold ‘Em, or Double Down?
Cardiogenic shock (CS) remains a leading cause of mortality in patients with acute myocardial infarction (AMI), and its incidence is increasing.1 While mortality has exceeded…
